View Information Collection Request (ICR) Package
Skip to main content
An official website of the United States government
The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Search:
Agenda
Reg Review
ICR
This script is used to control the display of information in this page.
Display additional information by clicking on the following:
All
Brief and OIRA conclusion
Abstract/Justification
Legal Statutes
Rulemaking
FR Notices/Comments
IC List
Burden
Misc.
Common Form Info.
Certification
View Information Collection (IC) List
View Supporting Statement and Other Documents
Please note that the OMB number and expiration date may not have been determined when this Information Collection Request and associated Information Collection forms were submitted to OMB. The approved OMB number and expiration date may be found by clicking on the Notice of Action link below.
View ICR - OIRA Conclusion
OMB Control No:
0910-0308
ICR Reference No:
202403-0910-011
Status:
Active
Previous ICR Reference No:
202303-0910-016
Agency/Subagency:
HHS/FDA
Agency Tracking No:
CBER
Title:
Biological Products; General records and postmarket adverse experience reporting
Type of Information Collection:
Extension without change of a currently approved collection
Common Form ICR:
No
Type of Review Request:
Regular
OIRA Conclusion Action:
Approved with change
Conclusion Date:
09/10/2024
Retrieve Notice of Action (NOA)
Date Received in OIRA:
04/26/2024
Terms of Clearance:
Inventory as of this Action
Requested
Previously Approved
Expiration Date
09/30/2027
36 Months From Approved
09/30/2024
Responses
1,178,806
0
715,688
Time Burden (Hours)
9,286,357
0
5,914,444
Cost Burden (Dollars)
0
0
0
Abstract:
This information collection supports Food and Drug Administration (FDA) regulations regarding certain general requirements and postmarket adverse experience reporting for biological products. Respondents to the collection are manufacturers of these products subject to the applicable regulations. The information collection enables FDA to implement public health protection provisions of the Federal Food, Drug, and Cosmetic Act.
Authorizing Statute(s):
US Code:
21 USC 301 et seq.
Name of Law: FFDCA
US Code:
42 USC 262
Name of Law: PHS Act
Citations for New Statutory Requirements:
None
Associated Rulemaking Information
RIN:
Stage of Rulemaking:
Federal Register Citation:
Date:
Not associated with rulemaking
Federal Register Notices & Comments
60-day Notice:
Federal Register Citation:
Citation Date:
88 FR 66856
09/28/2023
30-day Notice:
Federal Register Citation:
Citation Date:
89 FR 17858
03/12/2024
Did the Agency receive public comments on this ICR?
Yes
Number of Information Collection (IC) in this ICR:
3
IC Title
Form No.
Form Name
Biological products Reporting
3500A, VAERS-1
MEDWATCH
,
Vaccine Adverse Event Reporting System
Biological products; Recordkeeping
3500A, VAERS-1
MEDWATCH
,
Vaccine Adverse Event Reporting System
Postmarketing Safety Reporting for Combination Biological Products
ICR Summary of Burden
Total Approved
Previously Approved
Change Due to New Statute
Change Due to Agency Discretion
Change Due to Adjustment in Estimate
Change Due to Potential Violation of the PRA
Annual Number of Responses
1,178,806
715,688
0
0
463,118
0
Annual Time Burden (Hours)
9,286,357
5,914,444
0
0
3,371,913
0
Annual Cost Burden (Dollars)
0
0
0
0
0
0
Burden increases because of Program Change due to Agency Discretion:
No
Burden Increase Due to:
Burden decreases because of Program Change due to Agency Discretion:
No
Burden Reduction Due to:
Short Statement:
The information collection reflects adjustment. As communicated in Q-12 above, on March 20, 2023, we requested, and OMB approved, the addition of burden attributable to provisions set forth in part 4, subpart B, previously included in OMB control number 0910–0834. Upon this submission, however, we noted an inadvertent recording overage (+20hrs) and have corrected it with this submission (thereby reflecting a -20 hr. reduction). Additionally, our evaluation shows a spike of reporting with regard to 15-day alerts and periodic AERs, along with the corresponding recordkeeping, during years 2021 and 2022. At the same time, the number of respondents to the collection of information has remained fairly constant, noting that we reported 103 licensed biologics manufacturing respondents in 2021 and currently we report 109 licensed biologics manufacturing respondents (please see Q-12). Similarly, burden attributable to distribution reports, recalls, and waiver requests remains rather constant, where our current review reflects nominal adjustments for this activity, and the time per activity is unchanged. As of 2023, however, numbers associated with AERs have begun to decline and we expect this trend to continue as reports associated with vaccine products stabilizes.
Annual Cost to Federal Government:
$21,707,968
Does this IC contain surveys, censuses, or employ statistical methods?
No
Does this ICR request any personally identifiable information (see
OMB Circular No. A-130
for an explanation of this term)? Please consult with your agency's privacy program when making this determination.
No
Does this ICR include a form that requires a Privacy Act Statement (see
5 U.S.C. §552a(e)(3)
)? Please consult with your agency's privacy program when making this determination.
No
Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]?
No
Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]?
No
Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)?
No
Is this ICR related to the Pandemic Response?
No
Agency Contact:
Domini Bean 301 796-5733 domini.bean@fda.hhs.gov
Common Form ICR:
No
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(a) It is necessary for the proper performance of agency functions;
(b) It avoids unnecessary duplication;
(c) It reduces burden on small entities;
(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;
(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;
(f) It indicates the retention periods for recordkeeping requirements;
(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.
(i) It uses effective and efficient statistical survey methodology (if applicable); and
(j) It makes appropriate use of information technology.
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
Certification Date:
04/26/2024
An official website of the United States government
The .gov means it's official.
The site is secure.
